Literature DB >> 10952445

Prevention of transplacental transmission of moderate-virulent classical swine fever virus after single or double vaccination with an E2 subunit vaccine.

A J de Smit1, A Bouma, E P de Kluijver, C Terpstra, R J Moormann.   

Abstract

The use of a vaccine against classical swine fever virus (CSFV) during an outbreak of CSF should lead to a reduction in the horizontal or vertical transmission of CSFV. The reduction of vertical, i.e. transplacental, transmission of a moderate-virulent strain of CSFV from the sow to its offspring was studied in sows vaccinated once or twice with a CSFV E2 subunit vaccine. Two groups of nine sows were vaccinated with one PD95 dose of the E2 subunit vaccine, approximately four weeks before insemination. A third group of nine inseminated sows served as controls. One group of nine sows were vaccinated again at two weeks after insemination. At ten weeks after the primary vaccination, approximately six weeks after insemination, all 27 sows were challenged intranasally with 10(5) TCID50 of a moderate-virulent strain of CSFV, the Van Zoelen strain. The sows were euthanized at five weeks after challenge, and samples from the sows and fetuses were collected for detection of CSFV. All 27 sows were in gestation at the time of slaughter, CSFV was detected in the fetuses of all unvaccinated sows but it was not detected in any of the samples collected from fetuses of the double-vaccinated sows. Virus was however recovered from the fetuses of one out of nine sows vaccinated once. All the sows, except four double-vaccinated sows, developed CSFV Erns antibodies. Transplacental transmission of CSFV was reduced significantly (p <0.001) in all vaccinated sows. When the results from the experiment were extrapolated to a herd level, it could be concluded that, with 95% certainty, approximately 11% (single vaccination) or 0% (double vaccination), confidence intervals of 0.01-0.44 and 0.0-0.30 respectively, of the pregnant sows would still not be protected against vertical transmission of moderate-virulent CSFV. We conclude that vaccination with the CSFV E2 subunit vaccine can reduce the transmission of moderate-virulent strain of CSFV from the sow to its offspring significantly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952445     DOI: 10.1080/01652176.2000.9695045

Source DB:  PubMed          Journal:  Vet Q        ISSN: 0165-2176            Impact factor:   3.320


  6 in total

1.  Molecular characterization of E2 glycoprotein of classical swine fever virus: adaptation and propagation in porcine kidney cells.

Authors:  Rakesh Kumar; Nagendra N Barman; Elina Khatoon; Gitika Rajbongshi; Nipu Deka; Sudhir Morla; Sachin Kumar
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-01-01       Impact factor: 2.416

Review 2.  Research Progress and Challenges in Vaccine Development against Classical Swine Fever Virus.

Authors:  Qiang Wei; Yunchao Liu; Gaiping Zhang
Journal:  Viruses       Date:  2021-03-10       Impact factor: 5.048

3.  Comparison of antibody values in sera of pigs vaccinated with a subunit or an attenuated vaccine against classical swine fever.

Authors:  S Terzić; L Jemersić; M Lojkić; J Madić; J Grom; I Toplak; L Sver; I Valpotić
Journal:  Vet Res Commun       Date:  2003-05       Impact factor: 2.816

4.  Efficacy of a live attenuated vaccine in classical swine fever virus postnatally persistently infected pigs.

Authors:  Sara Muñoz-González; Marta Perez-Simó; Marta Muñoz; José Alejandro Bohorquez; Rosa Rosell; Artur Summerfield; Mariano Domingo; Nicolas Ruggli; Llilianne Ganges
Journal:  Vet Res       Date:  2015-07-09       Impact factor: 3.683

5.  Generation and efficacy evaluation of recombinant classical swine fever virus E2 glycoprotein expressed in stable transgenic mammalian cell line.

Authors:  Rong-Hong Hua; Hong Huo; Ye-Nan Li; Yao Xue; Xiao-Lei Wang; Li-Ping Guo; Bin Zhou; Yong Song; Zhi-Gao Bu
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

Review 6.  Classical Swine Fever-An Updated Review.

Authors:  Sandra Blome; Christoph Staubach; Julia Henke; Jolene Carlson; Martin Beer
Journal:  Viruses       Date:  2017-04-21       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.